The Partnering Agreements with Cubist report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
The Partnering Agreements with Cubist report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
The timing may be right for a takeover of Cubist Pharmaceuticals.
Cubist has acquired a few companies in the last five years with its biggest purchase of $800 million of Optimer Pharmaceuticals.
Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.
Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.
Rumors swirl about the possibility of Optimer Pharmaceuticals being an acquisition target in the coming weeks
Cubist, a leading biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years
Isis Pharmaceuticals is an antisense drug discovery technology company developing therapies for a number of serious diseases.
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.
Preclinical stage partnering refers to a commercial deal or alliance signed when a compound or product…
Acquisition rumours fly as GlaxoSmithKline, Astellas Cubist and AstraZeneca said to be interested in Optimer Pharmaceuticals takeover
Sorry, your search returned no results.
Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.
Cubist Pharmaceuticals has upped the size of its financing offering of convertible notes to as much at $800 million, including overallotments, to pay for its acquisition of Optimer Pharmaceuticals.
Big biotech, Cubist Pharmaceuticals, announced its intention to commence a financing offering, subject to market and other conditions, of $600 million in convertible senior unsecured notes that are expected to be issued in two $300 million series
Cubist Pharmaceuticals and Optimer Pharmaceuticals seal merger and acquisition activity under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis
M&A news: Cubist Pharmaceuticals, and Trius Therapeutics have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or approximately $707 million on a fully diluted basis
Rumors swirl about the possibility of Optimer Pharmaceuticals being an acquisition target in the coming weeks
Cubist Pharmaceuticals and Astellas Pharma have entered into a pharma licensing agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas.
Cubist Pharmaceuticals, a big biotech company, and Adynxx have entered into an option agreement under which Cubist explores biotech partnering with Adynxx.
Cepheid announced a new pharma deal with AstraZeneca, Cubist Pharmaceuticals, and GSK intended to promote transformational change in infectious disease therapy.
Acquisition rumours fly as GlaxoSmithKline, Astellas Cubist and AstraZeneca said to be interested in Optimer Pharmaceuticals takeover